Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study.RMD Open. 2020; 6: e001392
- Venous thromboembolism in patients with autoimmune disorders: a comparison between bleeding complications during anticoagulation and recurrences after its discontinuation.Br J Haematol. 2022; 197: 489-496
- Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.J Thromb Thrombolysis. 2014; 38: 306-313
- Waiting for JAK inhibitor safety data.RMD Open. 2022; 8: e002236
- Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis.Eur Rev Med Pharmacol Sci. 2021; 25: 7005-7013
- The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.Rheumatology (Oxford). 2021; 60: 188-195
- Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.Ann Rheum Dis. 2021; 80: 169-175
- Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?.RMD Open. 2021; 7: e001618
- Circulating Adipokines and Associations with Incident Cardiovascular Disease in Rheumatoid Arthritis.Arthritis Care Res (Hoboken). 2022; (In press)https://doi.org/10.1002/acr.24885
- Ankylosing spondylitis and risk of venous thromboembolism: A systematic review and meta-analysis.Lung India. 2016; 33: 642-645
- Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study.Arthritis Res Ther. 2017; 19: 102
- Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?.Ann Rheum Dis. 2017; 76: 364-370
- Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study.Ann Rheum Dis. 2019; 78: 480-485
- Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.Eur Heart J. 2018; 39: 3608-3614
- The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study.Arthritis Res Ther. 2022; 24: 16
- The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis.Semin Arthritis Rheum. 2021; 51: 547-552
- Risk of Venous Thromboembolism in Ankylosing Spondylitis and Rheumatoid Arthritis: Genetic Aspects.J Rheumatol. 2021; 48: 1492-1493
- Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus.J Am Coll Cardiol. 2021; 77: 1717-1727
- The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.Semin Arthritis Rheum. 2015; 45: 195-201
- Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.Clin Rheumatol. 2010; 29: 599-604
- Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups.Arthritis Rheum. 2005; 52: 2774-2782
- Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study.Lupus. 2017; 26: 1435-1439
- High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth.Arthritis Care Res (Hoboken). 2018; 70: 1303-1311
- Clinical characteristics of systemic lupus erythematosus patients in long-term remission without treatment.Clin Rheumatol. 2020; 39: 3365-3371
- Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011.ACR Open Rheumatol. 2019; 1: 194-200
- Venous Thromboembolic Events in African American Lupus Patients in Association With Antiphospholipid Antibodies Compared to White Patients.Arthritis Care Res (Hoboken). 2022; 74: 656-664
- Association of Lupus Nephritis Histopathologic Classification With Venous Thromboembolism-Modification by Age at Biopsy.Kidney Int Rep. 2021; 6: 1653-1660
- Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients.Medicine. 2003; 82: 299-308
- Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause.J Clin Rheumatol. 2013; 19: 421-425
- The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus.Blood. 2004; 104: 143-148
- Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.Scand J Rheumatol. 2007; 36: 198-205
- Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE.Lupus. 2021; 30: 1289-1299
- Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.Clin Chem. 2005; 51: 545-552
- Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?.Rheumatology (Oxford). 2021; 60: 1376-1386
- Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.Rheumatology (Oxford). 2020; 59: 3264-3274
- Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus.Clin Exp Rheumatol. 2021; 39: 1360-1368
- Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism.J Thromb Haemost. 2020; 18: 926-930
- Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.Semin Immunopathol. 2022; 44: 347-362
- Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry.Lupus. 2020; (In press)https://doi.org/10.1177/0961203320940776
- Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study.Thromb Res. 2022; 209: 69-74
- Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management.J Heart Lung Transpl. 2022; 41: 208-216
- Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis.J Rheumatol. 2015; 42: 1786-1793
- Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism.Sci Rep. 2018; 8: 17301
- Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.Rheumatology (Oxford). 2018; 57: 1340-1349
- Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study.Mayo Clin Proc. 2018; 93: 597-606
- Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.Clin Rheumatol. 2021; 40: 2843-2853
- Mechanisms of thrombosis in ANCA-associated vasculitis.Clin Rheumatol. 2021; 40: 4807-4815
- Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data.Ann Rheum Dis. 2019; 78: 261-269
- Inpatient burden and association with comorbidities of polyarteritis nodosa: National Inpatient Sample 2014.Semin Arthritis Rheum. 2020; 50: 66-70
- Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis.Clin Rheumatol. 2016; 35: 2741-2747
- Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.Arthritis Rheumatol. 2017; 69: 176-184
- Risk of venous and arterial thromboembolism in patients with giant cell arteritis and/or polymyalgia rheumatica: A Veterans Health Administration population-based study in the United States.J Intern Med. 2022; 291: 665-675
- Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency.Rheumatology (Oxford). 2015; 54: 1360-1368
- Thromboembolism and venous thrombosis of the deep veins in surgical children--an increasing challenge?.J Pediatr Surg. 2011; 46: 433-436
- Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN).Rheumatology (Oxford). 2020; 59: 2785-2795
- Clinical features and management of venous thromboembolism in patients with Behçet's syndrome: a single-center case-control study.Intern Emerg Med. 2020; 15: 635-644
- Activated protein C levels in Behçet's disease and risk of venous thrombosis.Br J Haematol. 2004; 126: 550-556
- Activated protein C resistance in Behcet's disease.Thromb J. 2013; 11: 17
- Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.Blood Adv. 2021; 5: 3203-3215
- Thrombotic manifestations of VEXAS syndrome.Semin Hematol. 2021; 58: 230-238
- Risk of venous thromboembolism in patients with Sjögren's syndrome: a systematic review and meta-analysis.Clin Exp Rheumatol. 2015; 33: 746-750
- The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjögren Syndrome: A General Population-based Study.J Rheumatol. 2017; 44: 1184-1189
- Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.J Intern Med. 2019; 286: 458-468
- Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis.Ther Clin Risk Manag. 2018; 14: 157-165
- Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.Ann Rheum Dis. 2016; 75: 110-116
- Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study.Thromb Res. 2014; 134: 622-626
- Idiopathic Inflammatory Myopathy and Venous Thromboembolic Events: Comment on the Article by Antovic et al.Arthritis Care Res (Hoboken). 2019; 71: 1396
- Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis.Mod Rheumatol. 2015; 25: 893-897
- Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study.J Am Heart Assoc. 2019; 8: e013405
- Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study.Arthritis Care Res (Hoboken). 2016; 68: 246-253
- Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival.J Rheumatol. 2018; 45: 942-946
- High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular complications.J Scleroderma Relat Disord. 2021; 6: 178-186
- Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study.J Thromb Haemost. 2012; 10: 815-821
- Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children.Am J Epidemiol. 2021; 190: 403-412
- Sarcoidosis and risk of venous thromboembolism: A systematic review and meta-analysis.Sarcoidosis Vasc Diffuse Lung Dis. 2015; 32: 182-187
- Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.Reumatismo. 2017; 69: 16-22
- Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013.Chest. 2017; 151: 425-430
- Sarcoidosis in the United States Military Health System.Sarcoidosis Vasc Diffuse Lung Dis. 2018; 35: 261-267
- Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism.Am J Cardiol. 2021; 149: 112-118
- The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis.Rheumatol Int. 2021; 41: 1209-1219
- Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study.Rheumatology (Oxford). 2020; 59: 1099-1107
- Venous thromboembolism in patients with gout and the impact of hospital admission, disease duration and urate-lowering therapy.CMAJ. 2019; 191: E597-E603
- Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.Chest. 2016; 149: 315-352
- EULAR recommendations for the management of antiphospholipid syndrome in adults.Ann Rheum Dis. 2019; 78: 1296-1304
- Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.Eur J Intern Med. 2020; 79: 43-50
- Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.Autoimmun Rev. 2021; 20: 102711
- Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy.Clin Exp Rheumatol. 2013; 31: 877-882
- Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.Semin Arthritis Rheum. 2021; 51: 1242-1250
- Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.Arthritis Care Res (Hoboken). 2021; (In press)https://doi.org/10.1002/acr.24850
- Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study.Sci Rep. 2021; 11: 17009
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.Arthritis Rheum. 2011; 63: 877-883
- The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.Eur Heart J. 2021; 42: 4389-4400
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med. 2022; 386: 316-326
- Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past, Present, and Future.N Engl J Med. 2022; 386: 387-389
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.Ann Rheum Dis. 2020; 79: 1400-1413
- Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.Rheumatology (Oxford). 2021; 61: 121-130
- Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.RMD Open. 2022; 8: e002012
- Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.Arthritis Rheumatol. 2021; 73: 779-788
- POS0237 major adverse cardiovascular events, malignancies and venous thromboembolism by baseline cardiovascular risk: a post hoc analysis of oral surveillance.Ann Rheum Dis. 2022; 81: 356
- POS0239 risk of venous thromboembolic events in patients with rheumatoid arthritis aged ≥50 years with ≥1 cardiovascular risk factor: results from a phase 3b/4 randomised study of tofacitinib vs tumour necrosis factor inhibitors.Ann Rheum Dis. 2022; 81: 358
- Behçet's Syndrome and Thrombosis.Mediterr J Hematol Infect Dis. 2011; 3: e2011026
- Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review.BMC Rheumatol. 2018; 2: 2
- Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.Adv Ther. 2018; 35: 439-456
- Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.Pulm Circ. 2018; 8 (2045894018791358)
- Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.Integr Blood Press Control. 2020; 13: 15-29
- Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.Arthritis Res Ther. 2014; 16: 428
- Risk of venous thromboembolism in patients with rheumatoid arthritis.Arthritis Care Res (Hoboken). 2013; 65: 1600-1607
- Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study.J Thromb Haemost. 2012; 10: 2068-2074
- Combined oral contraceptive use and the risk of systemic lupus erythematosus.Arthritis Rheum. 2009; 61: 476-481
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
